NCT02555111View on ClinicalTrials.gov

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

PHASE3CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions
Deep Vein ThrombosisChronic Portal Vein Thrombosis
Interventions
DRUG

Xarelto

15mg/day oral administration during 2 to 4 years (based on the recruitment date).

Trial Locations (1)

92110

Hôpital Beaujon, Clichy

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02555111 - Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. | Biotech Hunter | Biotech Hunter